Core Viewpoint - Boston Scientific Corporation is facing a class action securities lawsuit due to alleged securities fraud that affected investors between July 23, 2025, and February 3, 2026 [1] Group 1: Lawsuit Details - The lawsuit claims that Boston Scientific's management provided overly positive statements while concealing material adverse facts about the U.S. electrophysiology (EP) segment, including the unsustainable growth rate and an earlier-than-expected tipping point [2] - Following the release of disappointing fourth quarter and full year 2025 results, including a significant miss in U.S. EP sales, the company issued guidance for fiscal 2026 that was well below market expectations [2] - On February 4, 2026, Boston Scientific's stock price dropped from $91.62 to $75.50, a decline of approximately 17.6% in one day, following the negative news [2] Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until May 4, 2026, to request to be appointed as lead plaintiff in the lawsuit [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - A class action securities lawsuit has been filed against Beyond Meat, Inc. for alleged securities fraud affecting investors between February 27, 2025, and November 11, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that Beyond Meat's defendants made false statements regarding the book value of certain long-lived assets, which exceeded their fair value, indicating a likely need for a material, non-cash impairment charge [2]. - It is claimed that this situation could impair Beyond Meat's ability to timely file periodic reports with the SEC, rendering the defendants' public statements materially false and misleading [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until March 24, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Zynex, Inc. for alleged securities fraud affecting investors between February 25, 2021, and December 15, 2025 [1] Group 1: Allegations and Company Practices - The lawsuit alleges that Zynex shipped products, including electrodes, in excess of need, inflating its revenue [2] - It is claimed that Zynex's practice of filing false claims drew scrutiny from insurers, including the health insurance program, Tricare [2] - Travelers initiated an action against Zynex and its executives, alleging a fraudulent overbilling scheme and seeking over $23 million in damages related to hundreds of fraudulent claims from 2018 to 2023 [2] - The management prioritized aggressive sales strategies over compliance with industry laws, leading to illegal overbilling practices [2] - The audit committee allegedly acted with reckless disregard for the underlying fraud, helping to bolster the Company's stock price through stock repurchase plans [2] Group 2: Legal Process and Participation - Investors who suffered losses in Zynex, Inc. during the relevant time frame have until April 21, 2026, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a track record of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - A class action securities lawsuit has been filed against Picard Medical, Inc. for alleged securities fraud affecting investors between September 2, 2025, and October 31, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Picard Medical was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonation of financial professionals [2]. - It is alleged that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The complaint states that Picard's public statements and risk disclosures failed to mention the false rumors and artificial trading activity that influenced the stock price [2]. - As a result of these actions, the defendants' positive statements regarding the Company's business and prospects were deemed materially misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses in Picard Medical, Inc. during the specified timeframe have until April 3, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Plug Power Inc. for alleged securities fraud affecting investors between January 17, 2025, and November 13, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that defendants made false statements regarding the availability of funds from the U.S. Department of Energy's Loan Program, overstating the likelihood that these funds would be accessible to Plug Power [2]. - It is claimed that Plug Power was likely to shift towards less ambitious projects with lower commercial potential, contradicting previous public statements made by the company [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 3, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 20 years of experience [4].

Core Viewpoint - A class action securities lawsuit has been filed against Ardent Health, Inc. for alleged securities fraud affecting investors between July 18, 2024, and November 12, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Ardent Health misrepresented its accounts receivable framework, stating it relied on "detailed reviews of historical collections," while in reality, it utilized a "180-day cliff" for reserving accounts [2] - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectible accounts, leading to a materially false financial position [2] - Additionally, the company allegedly did not maintain sufficient professional malpractice liability insurance to cover claims, which was inadequate given the rising social inflationary pressures in medical malpractice cases [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified period have until March 9, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4]

Core Viewpoint - Institutional investors in Snowflake Inc. (NYSE: SNOW) are encouraged to evaluate lead plaintiff opportunities in a pending securities class action due to significant stock price declines attributed to misleading statements by the company [1][3]. Institutional Investor Impact - Snowflake has over 334 million shares outstanding, and the stock price fell by $41.72 per share, or 18.14%, following corrective disclosures on February 28, 2024 [2]. - The lawsuit claims that Snowflake and its officers made materially misleading statements regarding consumption patterns and revenue growth, impacting institutional investors who held shares during the class period [3][6]. Fiduciary Obligations - Fiduciaries are required to assess legal remedies when portfolio holdings experience losses due to alleged securities fraud, with the opportunity to serve as lead plaintiff allowing for selection of counsel and oversight of litigation strategy [5]. - The PSLRA favors institutional investors with the largest financial interest in the relief sought, and absent class members can still participate in recovery without being lead plaintiffs [5]. Portfolio Impact Assessment - The lawsuit alleges that Snowflake's stock price was artificially inflated by positive statements about consumption and revenue targets, which were later revised downwards, leading to a significant impact on institutional holders [6].

Core Viewpoint - Eos Energy Enterprises, Inc. is facing a class action lawsuit for securities fraud, with allegations that the company made false or misleading statements regarding its production capabilities and operational performance during the specified class period from November 5, 2025, to February 26, 2026 [1] Summary by Relevant Sections Lawsuit Details - The lawsuit claims that Eos Energy was unable to meet its production and capacity utilization targets as previously guided [1] - It is alleged that the company's battery line downtime exceeded industry norms and internal forecasts [1] - Delays in achieving quality targets for automated bipolar production are also cited as a concern [1] - The lawsuit states that Eos Energy's systems and processes were inadequate, leading to inaccurate public disclosures [1] - As a result of these issues, the positive statements made by the defendants about Eos Energy's business were misleading [1] Investor Information - Investors who purchased Eos Energy securities during the class period may be entitled to compensation without upfront costs through a contingency fee arrangement [1] - Interested parties can join the class action by contacting the Rosen Law Firm or visiting their website [1] - A lead plaintiff must be appointed by May 5, 2026, to represent the class in the lawsuit [1]

Core Viewpoint - Soleno Therapeutics, Inc. is facing a class action lawsuit for securities fraud due to misleading statements regarding the safety and commercial viability of its DCCR treatment [1] Group 1: Lawsuit Details - The Schall Law Firm is leading a class action lawsuit against Soleno Therapeutics for violations of the Securities Exchange Act of 1934 [1] - Investors who purchased Soleno's securities between March 26, 2025, and November 4, 2025, are encouraged to participate in the lawsuit before May 5, 2026 [1] - The lawsuit claims that Soleno made false and misleading statements about the safety concerns of its DCCR treatment revealed in a Phase 3 clinical trial [1] Group 2: Allegations Against Soleno - The company allegedly downplayed safety risks associated with its DCCR treatment, which had greater risks than disclosed [1] - The DCCR treatment was reported to have lower commercial viability and a heightened risk of adverse events [1] - Public statements made by Soleno were deemed false and materially misleading throughout the class period [1]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Soleno Therapeutics, Inc. for the period between March 26, 2025, and November 4, 2025, due to alleged misleading statements regarding the safety and commercial viability of its drug DCCR [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Soleno Therapeutics made false and misleading statements about the safety of its Phase 3 clinical trial for DCCR, particularly concerning issues of excess fluid retention in participants [5]. - The lawsuit alleges that the administration of DCCR posed greater safety risks than disclosed, impacting its commercial viability and leading to potential adverse events post-launch [5]. - Investors are encouraged to join the class action without any out-of-pocket fees through a contingency fee arrangement [2][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable $438 million recovery for investors in 2019 [4]. - Investors can join the class action by submitting a form or contacting the firm directly for more information [3][6].